MaxCyte Inc. | |
Stock Exchange | London Stock Exchange |
EPS |
GBP0.13 |
Market Cap |
GBP66.73 M |
Shares Outstanding |
51.33 M |
Public Float |
- |
Address |
22 Firstfield Road Gaithersburg Maryland 20878 United States |
Employees | - |
Website | http://www.maxcyte.com |
Updated | 07/08/2019 |
MaxCyte, Inc. enages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include MaxCyte STX, MaxCyte VLX, and MaxCyte GT. |